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Methylglyoxal, a byproduct of glucose metabolism, has been shown to be
elevated in the blood of diabetic patients and has been identified as an
intermediate in the production of advanced glycation end products. Due to its
structure, methylglyoxal is highly reactive with a wide range of cellular
components. Specifically in the formation of AGEs, methylglyoxal modifies a
select few amino acids and leads to final production of AGEs. The
accumulation of these AGEs can cause inflammation, oxidative stress and cell
3. Similarly, methylglyoxal is able to produce high levels of reactive
death
Figure 1: Structure of methylglyoxal.
oxygen species (ROS) within the cell via mitochondrial modification which
results in a loss of membrane potential and an increase in intracellular calcium concentrations. High levels of
ROS are damaging to the cell and can lead to alteration in gene expression, inflammatory responses, structural
changes, and cell death4. The effects and mechanism of methylglyoxal have not been fully elucidated.
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Figure 5: Higher doses of methylglyoxal (800 µM-2000 µM) significantly reduced viability in H9C2
myoblasts when compared to the control (n=4, *: p < 0.05 vs. control).

In order to reverse the effects of methylglyoxal, our study tests three compounds that have either been utilized
in the treatment of diabetes or have been shown to decrease the amount of AGEs in the cell. Metformin, a
common management medication for diabetics, works by lowering the level of endogenous methylglyoxal in
the body, thus decreasing the quantity of AGEs produced and lessening the production of ROS5.
Aminoguanidine hydrochloride and pyridoxamine dihydrochloride act to reduce levels of AGEs by inhibiting
one of the intermediate steps, therefore decreasing the effects of AGEs and decreasing the amount of ROS as
well6,7. Metformin, aminoguanidine hydrochloride, and pyridoxamine dihydrochloride utilize different
mechanisms that interfere with the development of AGEs in the body, but these protective properties have not
been tested with respect to cardiomyocytes.
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In this study we compared the effects of metformin, aminoguanidine hydrochloride, or pyridoxamine
dihydrochloride on methylglyoxal-induced cell damage and ROS production in H9C2 myoblast cells.
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Figure 3: Structure of aminoguanidine
hydrochloride.

Figure 4: Structure of pyridoxamine
dihydrochloride.

Measurement of cell viability: H9C2 rat myoblasts were seeded at 2x104 cells per well 24 hours prior to
experiment. For testing the dose-response of methylglyoxal, cells were treated with varying concentrations
(400 µM- 2000 µM) of methylglyoxal and incubated for 24 hours before analysis. To determine the protective
effects, cells were treated with metformin (1-40 mM), aminoguanidine hydrochloride (250 µM- 2000 µM) and
pyridoxamine dihydrochloride (0.1 µM - 15µM) in presence of methylglyoxal (1200 µM) and monitored for
dose dependent effects after 24 hours. Cell viability was assessed using CCK-8 assay (Dojindo Molecular
Technologies) after washing out all the compounds from medium. Moreover, cell morphology was observed
using microscopy. Cell viability was expressed as the ratio of CCK readings to the non-treated control.
Measurement of intracellular ROS by DCFDA: After H9C2 rat myoblasts were seeded for 24 hours, cell
media were replaced with 20 μM non-fluorescent dichlorofluorescein diacetate (DCFDA, Abcam) for 45
minutes to allow the dye to load into the cell. After washing out the unloaded DCFDA, the cells were
incubated with media containing 1200 µM methylglyoxal with metformin (1-40mM) or aminoguanidine
hydrochloride (250µm-8000µm). Inside the cell, DCFDA was deacetylated by cellular esterases to a nonfluorescent compound, which is later oxidized by ROS into a highly fluorescent compound2’, 7’ –
dichlorofluorescein (DCF). At 1 hour, 24 hours and >36 hours after treatment, fluorescence was measured at
excitation ( 488 nm) and emission (527 nm) using a Fluroskan Ascent CF scanner (Thermo scientific). The
change of ROS was expressed as the ratio to the baseline of non-treated control cells.
Statistical Analysis: All experiments were performed in triplicate and repeated at least three times. All values
are presented as a mean ± SE. The significance was examined by ANOVA Fischer’s PLSD. Values of p < 0.05
were considered statistically significant.
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We found that higher doses of methylglyoxal reduced cell viability in a dose- dependent manner which may be
related to increased levels of ROS within the cell. However, when methylglyoxal was introduced with
metformin, aminoguanidine hydrochloride, or pyridoxamine dihydrochloride, cell viability was significantly
improved (p <0.05 ). Meanwhile, higher intracellular ROS caused by methylglyoxal was significantly
decreased in the presence of metformin or aminoguanidine dihydrochloride. Future studies will investigate
mitochondrial function and the possible mechanisms underlying the effects of methylglyoxal, metformin and
aminoguanidine hydrochloride.
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We hypothesized that methylglyoxal reduced viability of H9C2 myoblast cells in a dose-dependent manner by
increasing free radicals. By contrast, concurrently treated with both methylglyoxal and either metformin,
aminoguanidine hydrochloride, or pyridoxamine dihydrochloride would increase cell viability accompanied
with reduction of free radicals .
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Figure 6: At 24 hours, higher doses of methylglyoxal (800 µM-2000 µM) showed significantly increased
levels of ROS production compared to the control (n=3, *: p < 0.05 vs. control).
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Figure 9: (A) Metformin showed a significant dose dependent reduction of ROS in H9C2 cells after 24 hours of
incubation with methylglyoxal (n=3, *: p < 0.05 vs. control). (B) Aminoguanidine hydrochloride illustrated
ROS reduction in higher doses after 24 hours when treated concurrently with methylglyoxal (n=3, *: p < 0.05
vs. control). Both metformin and aminoguanidine hydrochloride indicate significant protective effects against
methylglyoxal- induced ROS.

0.00
Figure 2: Structure of metformin.
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Figure 8: Representative microscopy of H9C2 cells (10X) under control, methylglyoxal 1200 µM, metformin
40 mM + methylglyoxal 1200 µM and aminoguanidine hydrochloride 8000 µM + methylglyoxal 1200 µM.
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Cardiovascular disease is one of the many complications that can arise from diabetes1. Diabetic patients may
undergo two main cellular changes regardless if glucose concentrations are properly maintained: advanced
glycation of end (AGE) products and overwhelming oxidative stress within the cell. Although low levels of
AGE are found normally at a basal level within the blood, diabetics have shown to have an increased level that
may lead to atherosclerosis in vasculature2.

Methylglyoxal 1200 µM

Control

*

*

*

100.00

*
*

80.00
60.00
40.00
20.00
0.00

1. Hegab, Z. (2012). Role of advanced glycation end products in cardiovascular disease. World Journal of
Cardiology, 4(4), 90. doi:10.4330/wjc.v4.i4.90
2. Caprnda, M., Mesarosova, D., Ortega, P. F., Krahulec, B., Egom, E., Rodrigo, L., . . . Gaspar, L. (2017).
Glycemic Variability and Vascular Complications in Patients with Type 2 Diabetes Mellitus. Folia Medica,
59(3), 270-278. doi:10.1515/folmed-2017-0048
3. Seo, K., Ki, S. H., & Shin, S. M. (2014). Methylglyoxal Induces Mitochondrial Dysfunction and Cell Death
in Liver. Toxicological Research, 30(3), 193-198. doi:10.5487/tr.2014.30.3.193
4. Chan, C., Huang, D., Huang, Y., Hsu, S., Kang, L., Shen, C., & Lin, W. (2016). Methylglyoxal induces cell
death through endoplasmic reticulum stress-associated ROS production and mitochondrial dysfunction. Journal
of Cellular and Molecular Medicine, 20(9), 1749-1760. doi:10.1111/jcmm.12893
5. Zhou, Z., Tang, Y., Jin, X., Chen, C., Lu, Y., Liu, L., & Shen, C. (2016). Metformin Inhibits Advanced
Glycation End Products-Induced Inflammatory Response in Murine Macrophages Partly through AMPK
Activation and RAGE/NFκB Pathway Suppression. Journal of Diabetes Research, 2016, 1-10.
doi:10.1155/2016/4847812
6. Carvalho, V. F., Florim, L. T., Barreto, E. D., Torres, R. C., Batista, M. M., Amendoeira, F. C., . . . Silva, P.
M. (2011). Inhibition of advanced glycation end products by aminoguanidine restores mast cell numbers and
reactivity in alloxan-diabetic rats. European Journal of Pharmacology, 669(1-3), 143-148.
doi:10.1016/j.ejphar.2011.08.004
7. Muellenbach, E. A., Diehl, C. J., Teachey, M. K., Lindborg, K. A., Archuleta, T. L., Harrell, N. B., . . .
Henriksen, E. J. (2008). Interactions of the advanced glycation end product inhibitor pyridoxamine and the
antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat. Metabolism, 57(10), 1465-1472.
doi:10.1016/j.metabol.2008.05.018

+ 1200 µM methylglyoxal

Figure 7: High doses of metformin , aminoguanidine hydrochloride and pyridoxamine dihydrochloride
showed significant protection against methylglyoxal-induced cell death ( n=7, *: p < 0.05 vs methylglyoxal).
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